The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Open accessAbstract
RATIONALE: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic, toxicity, and cost considerations. Available data in mice and humans showed that an increase in dose may shorten the duration of tuberculosis treatment. OBJECTIVES: To evaluate the safety and tolerability, the pharmacokinetics, and the extended early bactericidal activity of increasing doses of rifampin. METHODS: Patients with drug-susceptible tuberculosis were enrolled into a control group of eight patients receiving the standard dose of 10 mg/kg rifampin, followed by consecutive experimental groups with 15 patients each receiving rifampin 20, 25, 30, and 35 mg/kg, respectively, for 14 days. In all patients isoniazid, pyrazinamide, and ethambutol were added in standard doses for the second 7 days of treatment. Safety, pharmacokinetics of rifampin, and fall in bacterial load were assessed. MEASUREMENTS AND MAIN RESULTS: Grade 1 and 2 adverse events were equally distributed between the five dose groups; there were five grade 3 events of which one was a possibly related hepatotoxicity. Areas under the time-concentration curves and peak serum concentrations of rifampin showed a more than proportional increase with dose. The daily fall in bacterial load over 14 days was 0.176, 0.168, 0.167, 0.265, and 0.261 log10 colony-forming units/ml sputum in the 10, 20, 25, 30, and 35 mg/kg groups, respectively. CONCLUSIONS: Two weeks of rifampin up to 35 mg/kg was safe and well tolerated. There was a nonlinear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups. Clinical trial registered with www.clinicaltrials.gov (NCT 01392911).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models for Categorical and Limited Dependent Variables.
MTW, & Long, J. S. (1997) · Journal of the American Statistical Association · doi:10.2307/2965458 · Cited by 6,898
Zimmerli, W., Trampuz, A., & Ochsner, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040181 · Cited by 3,116
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Jindani, A., Aber, V. R., Edwards, E. A., & Mitchison, D. A. (1980) · PubMed · doi:10.1164/arrd.1980.121.6.939 · Cited by 487
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., & Gumbo, T. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit352 · Cited by 444
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01533-06 · Cited by 345
Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Borm, G., Aarnoutse, R. E., & van Crevel, R. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70264-5 · Cited by 344
Self-citationPharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
Idiosyncratic drug reactions: the reactive metabolite syndromes
Knowles, S. R., Uetrecht, J., & Shear, N. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03137-8 · Cited by 331
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
Jindani, A., Doré, C. J., & Mitchison, D. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1125oc · Cited by 321
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Self-citationHorsburgh, C. R., Barry, C. E., & Lange, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1413919 · Cited by 323
Peloquin, C. A., Dorman, S. E., Vernon, A., Battista Migliori, G., & Nahid, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw679 · Cited by 6
Metadata
- Authors
- Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., Heinrich, N., Rehal, S., van Soolingen, D., van Ingen, J., Magis-Escurra, C., Burger, D., Plemper van Balen, G., & Aarnoutse, R. E.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 191
- Issue
- 9
- Pages
- 1058-1065
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2143942591
- Cited by
- 309
- References
- 23
- FWCI
- 27.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis. https://app.cochat.ai/papers/10.1164/rccm.201407-1264oc
- The paper
- Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., Heinrich, N., Rehal, S., van Soolingen, D., van Ingen, J., Magis-Escurra, C., Burger, D., Plemper van Balen, G., & Aarnoutse, R. E. (2015). A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201407-1264oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
